The first part of my talk will be devoted to the exploration the human intestinal microbiota and all the efforts developed today for its exhaustive analysis. will lead to the isolation of novel beneficial bacteria. This aspect will be illustrated by Faecalibacterium prausnitzii which is the first anti-inflammatory commensal bacterium that we identified based on human clinical data and not via a routine usual screening (1). The second part of my talk will be focussed on the prophylactic and curative possibilities offered by genetically engineered probiotics especially to deliver anti-inflammatory molecules at the mucosal level. I will particularly describe the results obtained with the delivery of antiproteases by recLAB in colitis murine models (2).
1. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6.
2. Motta JP, Bermúdez-Humarán LG, Deraison C, Martin L, Rolland C, Rousset P, Boue J, Dietrich G, Chapman K, Kharrat P, Vinel JP, Alric L, Mas E, Sallenave JM, Langella P, Vergnolle N. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med. 2012 Oct 31;4(158):158ra144.